Display options
Cite
Wagner MJ, Maki RG. Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol. 2013;3:9doi: 10.3389/fonc.2013.00009.
Wagner, M. J., & Maki, R. G. (2013). Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Frontiers in oncology, 39. https://doi.org/10.3389/fonc.2013.00009
Wagner, Michael J, and Maki, Robert G. "Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer." Frontiers in oncology vol. 3 (2013): 9. doi: https://doi.org/10.3389/fonc.2013.00009
Wagner MJ, Maki RG. Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer. Front Oncol. 2013 Feb 04;3:9. doi: 10.3389/fonc.2013.00009. eCollection 2013. PMID: 23383402; PMCID: PMC3563098.
Copy Download .nbib Format: NLM
Share it on

Front Oncol. 2013 Feb 04;3:9. doi: 10.3389/fonc.2013.00009. eCollection 2013.

Type 1 insulin-like growth factor receptor targeted therapies in pediatric cancer.

Frontiers in oncology

Michael J Wagner, Robert G Maki

Affiliations

  1. Department of Medicine, Mount Sinai Medical Center New York, NY, USA.

PMID: 23383402 PMCID: PMC3563098 DOI: 10.3389/fonc.2013.00009

Abstract

Data from over 20 years ago demonstrated potential use for insulin-like growth factor (IGF) signaling modulators, specifically with IGF-1R antagonists, in a variety of pediatric and adolescent cancers, particularly in sarcomas. However, in spite of promising preclinical data, IGF-1R inhibitors have not had the success as single agents that was originally hoped for in clinical trials. Several potential mechanisms exist by which tumors are resistant to IGF-1R inhibitors. Notably, these resistance mechanisms are currently best understood in Ewing sarcoma and alveolar rhabdomyosarcoma. Various treatment schema have been proposed as a potential way to overcome this resistance. The use of IGF-1R inhibitors, mechanisms of resistance, and current ongoing clinical studies using IGF-1R inhibitors in pediatric cancers are reviewed here.

Keywords: IGF-1R; insulin-like growth factor pathway; pediatric cancer; resistance mechanisms; sarcoma

References

  1. Pediatr Blood Cancer. 2008 Jun;50(6):1190-7 - PubMed
  2. Lancet. 2006 Oct 14;368(9544):1329-38 - PubMed
  3. Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75 - PubMed
  4. Pediatr Blood Cancer. 2009 Jul;52(7):767-71 - PubMed
  5. Int J Cancer. 2010 Dec 1;127(11):2718-22 - PubMed
  6. J Clin Oncol. 2010 Jun 20;28(18):3061-8 - PubMed
  7. Cancer Res. 2006 Jul 1;66(13):6570-8 - PubMed
  8. Cancer Res. 2007 Apr 1;67(7):3431-40 - PubMed
  9. J Clin Oncol. 2000 Nov 15;18(22):3794-803 - PubMed
  10. Cancer Res. 1998 Sep 15;58(18):4127-31 - PubMed
  11. Mol Cell Biol. 2004 Aug;24(16):7275-83 - PubMed
  12. Mol Cancer Ther. 2011 Apr;10(4):697-707 - PubMed
  13. Clin Cancer Res. 2008 May 15;14(10):3204-15 - PubMed
  14. Mol Endocrinol. 2012 Sep;26(9):1603-16 - PubMed
  15. Cancer Res. 2007 Oct 1;67(19):9084-8 - PubMed
  16. J Clin Oncol. 2009 Dec 1;27(34):5800-7 - PubMed
  17. J Surg Oncol. 2012 Mar;105(3):235-43 - PubMed
  18. J Clin Oncol. 2011 Dec 1;29(34):4534-40 - PubMed
  19. Cancer Res. 2010 Sep 15;70(18):7221-31 - PubMed
  20. PLoS One. 2012;7(10):e47109 - PubMed
  21. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3532-40 - PubMed
  22. Nat Rev Cancer. 2008 Dec;8(12):915-28 - PubMed
  23. Clin Cancer Res. 2010 Jul 1;16(13):3368-77 - PubMed
  24. Nat Rev Cancer. 2012 Dec;12(12):818-34 - PubMed
  25. Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 - PubMed
  26. J Clin Invest. 1990 Dec;86(6):1806-14 - PubMed
  27. Pediatr Blood Cancer. 2011 Apr;56(4):595-603 - PubMed
  28. Nat Rev Drug Discov. 2002 Oct;1(10):769-83 - PubMed
  29. J Cell Physiol. 2000 Apr;183(1):1-9 - PubMed
  30. Cancer Res. 2006 Dec 1;66(23):11148-55 - PubMed
  31. Pediatr Blood Cancer. 2012 May;58(5):729-35 - PubMed
  32. J Pediatr Hematol Oncol. 2012 May;34 Suppl 2:S69-72 - PubMed
  33. Cancer Res. 1999 Aug 1;59(15):3588-91 - PubMed
  34. J Pathol. 2008 Dec;216(4):428-39 - PubMed
  35. Oncogene. 2007 Mar 22;26(13):1932-40 - PubMed
  36. J Clin Oncol. 2012 Jan 20;30(3):256-62 - PubMed
  37. Cancer. 2009 Apr 1;115(7):1531-43 - PubMed
  38. Endocrinol Metab Clin North Am. 2012 Jun;41(2):335-50, vi - PubMed
  39. Lancet Oncol. 2010 Feb;11(2):129-35 - PubMed
  40. Eur J Cancer. 2012 Nov;48(17):3215-22 - PubMed
  41. Pediatr Blood Cancer. 2010 Jul 1;54(7):921-6 - PubMed
  42. Bull Cancer. 2009 Jul-Aug;96(7):E52-60 - PubMed
  43. J Clin Oncol. 2011 Dec 1;29(34):4541-7 - PubMed
  44. J Clin Oncol. 2010 Nov 20;28(33):4985-95 - PubMed
  45. Cancer Res. 1994 May 15;54(10):2803-7 - PubMed
  46. Cancer Res. 2010 Nov 1;70(21):8770-81 - PubMed
  47. J Clin Oncol. 2012 May 20;30(15):1849-56 - PubMed
  48. Clin Cancer Res. 2011 Feb 15;17(4):871-9 - PubMed
  49. Endocrinology. 1996 May;137(5):2051-8 - PubMed
  50. Cancer Res. 2008 Oct 1;68(19):8039-48 - PubMed
  51. Proc Natl Acad Sci U S A. 2012 May 15;109(20):E1267-76 - PubMed
  52. J Pediatr Hematol Oncol. 2005 Apr;27(4):179-87 - PubMed
  53. Cancer Res. 2010 Jan 15;70(2):512-9 - PubMed
  54. Am J Pathol. 1989 Dec;135(6):961-6 - PubMed
  55. Mol Cancer Ther. 2011 Aug;10(8):1407-18 - PubMed
  56. Clin Cancer Res. 2002 Jun;8(6):1822-30 - PubMed
  57. Nat Rev Mol Cell Biol. 2003 Mar;4(3):202-12 - PubMed
  58. Eur J Cancer. 2010 Dec;46(18):3251-62 - PubMed
  59. J Clin Invest. 1989 Sep;84(3):829-39 - PubMed
  60. J Pathol. 2009 Mar;217(4):469-82 - PubMed
  61. Oncogene. 2006 Feb 16;25(7):1042-52 - PubMed
  62. Clin Cancer Res. 2012 May 1;18(9):2625-31 - PubMed
  63. Lancet Oncol. 2004 Jan;5(1):37-46 - PubMed
  64. Endocrinology. 2001 Jan;142(1):108-13 - PubMed
  65. PLoS One. 2011;6(10):e26060 - PubMed
  66. Growth Horm IGF Res. 2001 Oct;11(5):289-97 - PubMed
  67. N Engl J Med. 2002 Aug 15;347(7):472-80 - PubMed
  68. N Engl J Med. 2010 Jun 10;362(23):2202-11 - PubMed
  69. Cancer Res. 2009 Jan 1;69(1):161-70 - PubMed

Publication Types